Fisher & Paykel Healthcare

Over the past two decades, our understanding of high flow therapy has evolved, resulting in the F&P Optiflow Duet™ Asymmetric interface. Learn more on our website https://bit.ly/3AMBii5

Need a quick refresher on nasal high flow therapy? Our NHF therapy foundations course provides an overview of the therapy, how it works and which patients NHF may be suitable for. It only takes 15 minutes, log into the Education Hub and start learning here: https://bit.ly/3ZqelKX

Get ready to expand your clinical practice with our in-depth webinar, The pathway of the COPD patient and high-flow therapy through the hospital. This must-attend learning opportunity will be presented by highly regarded practitioner Dr Matthew Trump, DO, FACP, FCCP. Join him on Thursday, December 19, as he reviews the pathophysiology of COPD and mechanisms of action for high-flow therapy. He will also discuss how high-flow therapy can support COPD patients at all stages of treatment. Sign up for one of two free events:   Morning: 9 am PST / 11 am CST / 12 pm EST https://lnkd.in/gRH3Z9cu Afternoon (recorded event): 1 pm PST / 3 pm CST / 4 pm EST https://lnkd.in/grT9acna

Integration of nasal high flow (NHF) across the hospital environment may support standardization of care, as there are a number of possible pathways for the use of NHF in infants outside of the pediatric intensive care unit. Learn more about NHF: https://bit.ly/4cVFMjI

Congratulations and thank you to our suppliers for taking positive strides in responsible sourcing and reducing environmental impact! At Fisher & Paykel Healthcare’s Supplier Sustainability event this year, we welcomed over 50 of our local and overseas suppliers who have been collaborating with us on our intention to create a positive lasting impact on society and the environment. Our suppliers gained insights from senior leaders on F&P’s approach to sustainability and environmental and social governance, and we recognised their valuable contributions to our sustainable procurement goals. Our first-ever supplier expo was a highlight, with suppliers showcasing their sustainable products and initiatives to the wider business. Partnering with our suppliers is crucial to verify and validate our environmental, social and ethical performance and theirs, so we can continuously improve this. We are pleased with the engagement and progress made by our suppliers as we work together to achieve our environmental and social responsibility objectives.

Asymmetry is clawsome! The Asymmetric™ F&P Optiflow Duet™ interface represents an evolution in our understanding of high-flow therapy over two decades. You see, while we live in a world that values perfection, we’ve come to learn there’s beauty in asymmetry. Mother Nature knows this too. Look at the feisty male lemon-yellow fiddler crab🦀, which has evolved to have one oversized claw that proves mighty useful when it comes to defence and finding a mate. Just as Austruca perplexa draws strength from its one weighty claw, an asymmetric cannula can be advantageous to those seeking respiratory support. In fact, using one small prong and one large prong can amplify two key mechanisms of action in the therapy. Visit https://lnkd.in/g6Y3iBFg to learn more about how our Optiflow high-flow interface works… oh, and discover a couple more fascinating creatures🦑 that are winning their way in the world just by looking a little different. F&P, Asymmetric and Optiflow Duet are trademarks of Fisher & Paykel Healthcare Limited.

Have you considered how an asymmetric nasal cannula could improve your patient's work of breathing and alveolar ventilation? 🫁 Watch to understand, then learn more on the F&P Education Hub: https://bit.ly/4g5gG3F #MakeYourFlowMatter

Over the past two decades, our understanding of high flow therapy has evolved, resulting in the F&P Optiflow Duet™ Asymmetric interface. Learn more on our website https://bit.ly/3AMBii5

The F&P Optiflow Junior 2+ XXL Nasal Interface features larger tubing than the Optiflow Junior 2 to offer the potential for using higher flow rates up to 50 L/min. Learn more about Optiflow Junior 2+: https://bit.ly/4cEfKBV

For neonates greater than 28 weeks’ gestational age, there is emerging evidence supporting the use of nasal high flow (NHF) for primary respiratory support with 'rescue' continuous positive airway pressure (CPAP) available. Learn more about NHF in the neonatal space: https://bit.ly/45Ywpxs